Upcoming webinar

From results to action: What APPs need to know about dd-cfDNA

Date: Tuesday, November 17, 2026
Time: 12:00 PM PT | 2:00 PM CT | 3:00 PM ET (60-minute webinar)
Registrants will receive a recording of the webinar approximately one week after the event.
Join us for a practical, APP-led discussion on integrating Prospera™ Heart with DQS testing into transplant care.
  • Explore how two different transplant centers define the role of an APP in this evolving world of post-transplant care.
  • Discover the benefits of integrating Prospera into the post-transplant workflow.
  • Discuss real-world cases where a non-invasive alternative to surveillance biopsy can help drive clinical decisions.
Whether you're considering using dd-cfDNA testing or looking to strengthen how it's used in your center, you'll leave with actionable insights on how to integrate Prospera into practice.

Register Now:

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:


Meg Fraser, DNP, ANP-C
Meg Fraser, DNP, ANP-C
Nurse Practitioner
University of Minnesota Physicians
Laura L. Peters, DNP, FNP-C
Laura L. Peters, DNP, FNP-C
Associate Professor, Nurse Practitioner
University of Colorado Anschutz Medical Center, Division of Cardiology
Prospera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy